上海伟测半导体科技股份有限公司2025 年半年度报告 公司代码：688372 公司简称：伟测科技 转债代码：118055 转债简称：伟测转债 上海伟测半导体科技股份有限公司 2025 年半年度报告 1 / 168 上海伟测半导体科技股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已在本半年度报告中详细阐述公司在经营过程中可能面临的各种风险及应对措施，敬请 查阅本报告第三节"管理层讨论与分析"中"四、风险因素"相关内容。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人骈文胜、主管会计工作负责人王沛及会计机构负责人（会计主管人员）徐芳声 明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本半年度报告所涉及的公司未来计划、发 ...

天融信科技集团股份有限公司 2025 年半年度报告全文 天融信科技集团股份有限公司 2025 年半年度报告 2025 年 08 月 天融信科技集团股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人李雪莹、主管会计工作负责人孔继阳及会计机构负责人(会计 主管人员)戴芳平声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 半年度报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺， 投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、预测 与承诺之间的差异。 公司存在原材料价格及供应风险、因下游行业采购特点造成的季节性收入 和盈利波动的风险、技术人才流失风险及税收优惠政策变化风险，敬请广大投 资者注意投资风险。详细内容请见本报告"第三节 管理层讨论与分析"之 "十、公司面临的风险和应对措施"。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 1 | 第一 ...

江苏华信新材料股份有限公司 2025 年半年度报告全文 江苏华信新材料股份有限公司 2025 年半年度报告 公告编号：2025-027 二○二五年八月 1 江苏华信新材料股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法 律责任。 公司负责人李振斌、主管会计工作负责人杨希颖及会计机构负责人(会计 主管人员)丁帅声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中所涉及的未来计划，发展战略、经营业绩的预计等前瞻性描述不 构成公司对投资者的实质承诺，投资者及相关人士均应当对此保持足够的风 险认识，并且应当理解计划、预测与承诺之间的差异，敬请投资者注意投资 风险。 公司存在的风险因素及应对措施详见本报告第三节"管理层讨论与分析" 中"十、公司面临的风险和应对措施"，敬请投资者注意阅读。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | | | | | | 第二节 公司简介和主要财务指标 江苏华信 ...

丽珠医药集团股份有限公司 2025 年半年度报告 2025 年 8 月 丽珠医药集团股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 重要提示 丽珠医药集团股份有限公司董事会、监事会及董事、监事、高级管理人员保证半年度报告（"本报告"）内 容的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 本公司负责人朱保国先生、主管会计工作负责人及会计机构负责人（会计主管人员）司燕霞女士声明：保 证本报告中二零二五年中期财务报表及附注（"财务报告"）的真实、准确、完整。 本报告已经本公司第十一届董事会第二十六次会议及本公司审计委员会审议通过。所有董事均已出席了审 议本报告的董事会会议。 本集团按《中国企业会计准则》编制的财务报告未经审计。 本报告第三节"管理层讨论与分析"中分析了公司未来发展可能面临的风险因素和应对策略情况，敬请投资 者留意查阅。 本报告涉及若干基于对未来政策和经济的主观假定和判断而作出的前瞻性陈述，不构成本公司对投资者的 实质承诺，该等陈述会受到风险、不明朗因素及假设的影响，实际结果可能与该等陈述有重大差异。投资 者应注意不恰当信赖或使用此类信 ...

广东鼎泰高科技术股份有限公司 2025 年半年度报告全文 2025-039 广东鼎泰高科技术股份有限公司 2025 年半年度报告 2025 年 8 月 1 广东鼎泰高科技术股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法 律责任。 公司负责人王馨、主管会计工作负责人徐辉及会计机构负责人(会计主管 人员)陈玲声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中涉及的未来发展规划等前瞻性陈述不构成公司对投资者的实质承 诺，敬请广大投资者理性投资，注意风险。 本公司在本报告"第三节 管理层讨论与分析"之"十、公司面临的风险 和应对措施"部分详细描述了公司未来经营中可能存在的风险，敬请投资者 关注相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 2 | | | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 6 | | | ...

[Important Notice, Table of Contents, and Definitions](index=2&type=section&id=第一节%20重要提示、目录和释义) [Important Notice and Risk Disclosure](index=2&type=section&id=重要提示与风险披露) Management confirms the report's accuracy, cautions on macroeconomic, policy, and accounts receivable risks, and states no profit distribution is planned - The company faces five major operating risks: - **Large-scale system solution implementation risks**: High project complexity and long implementation cycles may lead to delays due to planning flaws, technical failures, or changing client demands - **Major customer loss risks**: High customer concentration among large and medium-sized medical institutions means client loss would significantly impact sustainable development - **Management control and gross margin fluctuation risks**: Expanding business scope demands higher project management control, while overall solution business may reduce comprehensive gross margin - **Technology and talent loss risks**: As a technology-intensive industry, the stability of the core technical team is crucial, with risks of talent outflow and core technology leakage - **National policy and macroeconomic environment change risks**: National healthcare informatization policies offer industry opportunities, but significant policy or macroeconomic changes could introduce operational uncertainties[5](index=5&type=chunk)[7](index=7&type=chunk)[8](index=8&type=chunk)[10](index=10&type=chunk)[11](index=11&type=chunk) - The company plans **not to distribute cash dividends, issue bonus shares, or convert capital reserves into share capital**[13](index=13&type=chunk) [Definitions](index=8&type=section&id=释义) This section defines key terms, including company entities, industry-specific systems like HIS and CIS, the 'Digital Hospital Overall Solution,' and specifies the reporting period as H1 2025 [Company Profile and Key Financial Indicators](index=10&type=section&id=第二节%20公司简介和主要财务指标) [Company Profile](index=10&type=section&id=公司简介) Zhejiang Horen Technology Co., Ltd. (stock code: 300550), listed on the Shenzhen Stock Exchange, is represented by Zhao Chenhui, with no changes in registered address, office address, or information disclosure locations during the reporting period Company Basic Information | Item | Content | | :--- | :--- | | Stock Abbreviation | Horen Technology | | Stock Code | 300550 | | Listing Exchange | Shenzhen Stock Exchange | | Company Full Chinese Name | 浙江和仁科技股份有限公司 | | Legal Representative | Zhao Chenhui | [Key Accounting Data and Financial Indicators](index=11&type=section&id=主要会计数据和财务指标) In H1 2025, despite nearly flat revenue, the company significantly narrowed its net loss and improved operating cash flow, indicating an overall improvement in financial performance Key Financial Indicators for H1 2025 | Indicator | Current Period | Prior Period | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue (million yuan) | 158.88 | 160.46 | -0.99% | | Net Profit Attributable to Shareholders (million yuan) | -3.52 | -14.33 | 75.44% | | Net Profit Attributable to Shareholders (Excluding Non-recurring Items) (million yuan) | -4.41 | -15.98 | 72.38% | | Net Cash Flow from Operating Activities (million yuan) | -64.99 | -96.29 | 32.50% | | Basic Earnings Per Share (yuan/share) | -0.01 | -0.05 | 80.00% | | Weighted Average Return on Net Assets | -0.32% | -1.34% | 1.02% | Key Balance Sheet Indicators at Period End | Indicator | End of Current Period (billion yuan) | End of Prior Year (billion yuan) | Change from Beginning of Year | | :--- | :--- | :--- | :--- | | Total Assets | 1.44 | 1.46 | -1.56% | | Net Assets Attributable to Shareholders | 1.10 | 1.11 | -0.91% | - During the reporting period, the company's total non-recurring gains and losses amounted to **0.89 million yuan**, primarily from fair value changes in financial assets and government subsidies[33](index=33&type=chunk) [Management Discussion and Analysis](index=13&type=section&id=第三节%20管理层讨论与分析) [Main Business Activities During the Reporting Period](index=13&type=section&id=报告期内公司从事的主要业务) The company's core business involves R&D, sales, implementation, and service of medical information and digital scenario application systems, offering overall solutions to healthcare institutions, driven by national policies and AI advancements - The company's main business is divided into two segments: **Medical Information Systems** (including hospital clinical information systems centered on electronic medical records and city-level smart healthcare solutions) and **Digital Scenario Application Systems** (extensions of clinical information systems in various medical service scenarios, such as smart outpatient and smart surgery)[36](index=36&type=chunk)[37](index=37&type=chunk)[39](index=39&type=chunk) - The company's products support **domestic operating systems and databases** and feature **modular component assembly**, enhancing productization, meeting personalized needs, and reducing development costs[42](index=42&type=chunk)[43](index=43&type=chunk) - During the reporting period, the National Health Commission issued policies like the **'Smart Healthcare Grading Evaluation Method and Standards (2025 Edition)'** and **'Tier-3 Hospital Review Standards (2025 Edition)'**, emphasizing data interoperability, AI applications, and medical quality, providing clear guidance and market drivers for industry development[48](index=48&type=chunk)[49](index=49&type=chunk)[51](index=51&type=chunk) [Analysis of Core Competencies](index=17&type=section&id=核心竞争力分析) The company's core competencies include comprehensive solution capabilities based on proprietary clinical products, advanced technology, continuous innovation, full lifecycle services, premium client resources, and an experienced management and talent team - The company provides **top-down designed, hospital-wide smart hospital overall solutions** centered on clinical data interoperability, occupying a core position in medical informatization construction[58](index=58&type=chunk)[59](index=59&type=chunk) - The company's new-generation hospital information system is one of China's **largest core business systems based on HTML5 and cloud computing technology**, supporting cloud deployment, group hospital applications, and integrating HIS with EMR[62](index=62&type=chunk) - The company has established **long-term partnerships with top-tier large medical institutions** in military systems and multiple regions like Zhejiang, Jiangsu, Jiangxi, and Shaanxi, accumulating extensive successful cases and implementation experience[64](index=64&type=chunk) [Analysis of Main Business Operations](index=19&type=section&id=主营业务分析) During the reporting period, operating revenue slightly decreased, but a significant drop in operating costs boosted gross margin, while R&D investment substantially increased; medical information systems dominated revenue with improved gross margin, and regional performance varied, with strong growth in Central China Key Financial Data Year-on-Year Changes | Item | Current Period (million yuan) | Prior Period (million yuan) | YoY Change | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Cost | 89.92 | 112.59 | -20.14% | - | | Financial Expenses | -2.15 | -3.09 | 30.51% | Primarily due to decreased interest income | | R&D Investment | 31.72 | 23.63 | 34.27% | Primarily due to increased R&D investment in this period | | Net Cash Flow from Investing Activities | -40.74 | 9.98 | -508.22% | Primarily due to increased purchase of wealth management products | | Net Cash Flow from Financing Activities | -33.56 | -0.95 | -3,431.93% | Primarily due to decreased loans compared to the prior period | Operating Revenue by Product or Service (million yuan) | Product/Service | Operating Revenue (million yuan) | Operating Cost (million yuan) | Gross Margin | YoY Change in Operating Revenue | YoY Change in Operating Cost | YoY Change in Gross Margin | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Scenario-based Application Systems | 34.05 | 27.18 | 20.18% | -29.01% | -32.01% | 3.53% | | Medical Information Systems | 89.12 | 44.99 | 49.51% | 0.45% | -26.70% | 18.70% | Operating Revenue by Region (million yuan) | Region | Operating Revenue (million yuan) | YoY Change in Operating Revenue | Gross Margin | YoY Change in Gross Margin | | :--- | :--- | :--- | :--- | :--- | | Northwest Region | 81.77 | -11.10% | 53.98% | 26.81% | | East China Region | 37.73 | -39.49% | 41.60% | 8.08% | | Central China Region | 26.93 | 1,699.45% | 11.22% | -29.08% | [Analysis of Assets and Liabilities](index=21&type=section&id=资产及负债状况分析) At period-end, total assets decreased, with a notable shift in asset structure as cash declined and contract assets rose, while short-term borrowings decreased, and some cash remained restricted due to guarantees and litigation Significant Changes in Asset Composition | Item | Proportion of Total Assets at Period End | Proportion of Total Assets at Beginning of Year | Change in Proportion | | :--- | :--- | :--- | :--- | | Cash and Cash Equivalents | 28.05% | 37.08% | -9.03% | | Accounts Receivable | 22.08% | 20.66% | 1.42% | | Contract Assets | 25.59% | 20.71% | 4.88% | | Short-term Borrowings | 4.87% | 6.57% | -1.70% | - As of the end of the reporting period, **4.62 million yuan** of the company's cash and cash equivalents were restricted, primarily for bill deposits, letter of guarantee deposits, migrant worker wage guarantees, and litigation-frozen funds[81](index=81&type=chunk)[491](index=491&type=chunk) [Analysis of Investment Activities](index=22&type=section&id=投资状况分析) During the reporting period, the company's investment increased, primarily in wealth management products using own funds, with no significant equity, non-equity, or derivative investments Overview of Entrusted Wealth Management (million yuan) | Specific Type | Source of Funds for Entrusted Wealth Management | Amount of Entrusted Wealth Management Occurred (million yuan) | Unmatured Balance (million yuan) | | :--- | :--- | :--- | :--- | | Bank Wealth Management Products | Own Funds | 60 | 30 | [Analysis of Major Holding and Participating Companies](index=24&type=section&id=主要控股参股公司分析) The company established new subsidiaries and deregistered others to expand digital hospital business and enhance operational efficiency, with its main subsidiary, Zhejiang Meihe Institute, reporting a net loss - To accelerate digital hospital business expansion and market layout, the company established **Horen Health Technology Hong Kong Co., Ltd., Nanjing Horen Digital Medical Technology Co., Ltd., Wenzhou Shukangjian Technology Industry Development Co., Ltd., and Wenzhou Shujian Technology Co., Ltd.**[93](index=93&type=chunk)[134](index=134&type=chunk) - Due to business strategy adjustments, the company deregistered **Shanghai Horkangyi Technology Co., Ltd.** and established and then deregistered **Zhejiang Hezhong Renxin Technology Co., Ltd.**, neither of which had a substantial impact on operations or performance[93](index=93&type=chunk)[134](index=134&type=chunk) [Corporate Governance, Environment, and Society](index=27&type=section&id=第四节%20公司治理、环境和社会) [Corporate Governance and Social Responsibility](index=27&type=section&id=公司治理与社会责任) During the reporting period, there were no changes in the company's directors, supervisors, or senior management, no profit distribution or equity incentive plans, and the company actively fulfilled its social responsibilities by protecting stakeholder rights - There were **no changes in the company's directors, supervisors, and senior management** during the reporting period[103](index=103&type=chunk) - The company plans **not to distribute cash dividends, issue bonus shares, or convert capital reserves into share capital** for the half-year period[104](index=104&type=chunk) - The company actively fulfills its social responsibilities, focusing on **protecting the rights and interests of shareholders, employees, suppliers, and customers**[106](index=106&type=chunk)[107](index=107&type=chunk) [Significant Matters](index=29&type=section&id=第五节%20重要事项) [Litigation and Major Contracts](index=29&type=section&id=诉讼与重大合同) While no major litigation occurred, several other significant cases, including arbitration with PLA General Hospital and a lawsuit with Xi'an Construction Group, are ongoing; the company is also executing major smart hospital projects with Xinjiang TCM Hospital, Xi'an Honghui Hospital, and Xi'an Children's Hospital Other Litigation Matters (Partial) | Litigant | Amount Involved (million yuan) | Litigation Progress | | :--- | :--- | :--- | | Zhejiang Horen Technology vs. PLA General Hospital | 22.26 | Arbitration filed, not yet heard | | Zhejiang Horen Technology vs. Xi'an Construction Engineering Group Co., Ltd. et al. | 16.06 | Case filed, under normal trial | | Shanxi Zhijie Software Engineering Co., Ltd. vs. Zhejiang Horen Technology | 3.34 | Second instance judgment rendered, appeal dismissed, original judgment upheld | | Zhejiang Horen Technology vs. Nantong Yilian E-commerce Co., Ltd. | 2.79 | First instance judgment supported plaintiff, defendant appealed, second instance under trial | Performance of Major Daily Operating Contracts (Partial) | Client Name | Contract Content | Total Contract Amount (million yuan) | Overall Progress | | :--- | :--- | :--- | :--- | | Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine | Smart Hospital Informatization Project | 148.16 | 42.03% | | Xi'an Honghui Hospital | Multi-campus Integrated 'Smart Hospital' Scenario Application Project | 165.87 | 96.87% | | China Construction Eighth Engineering Division Second Construction Co., Ltd. | Xi'an Children's Hospital Jingkai Campus Project Intelligent Engineering | 148.91 | 66.05% | | PLA General Hospital | Subcontract for Low-Voltage Intelligent Engineering of Outpatient and Emergency Comprehensive Building | 141.41 | Accepted but not yet settled | [Share Changes and Shareholder Information](index=36&type=section&id=第六节%20股份变动及股东情况) [Share Changes and Shareholder Information](index=36&type=section&id=股份变动与股东情况) At period-end, the company's total share capital and shareholder count remained stable, with the top three shareholders identified, and the controlling shareholder's shares, along with its concerted parties, partially pledged - During the reporting period, the company's **total share capital remained unchanged at 262,560,141 shares**[137](index=137&type=chunk) Top Ten Shareholders' Shareholding | Shareholder Name | Shareholding Percentage | Number of Shares Held | | :--- | :--- | :--- | | Tongce Medical Co., Ltd. | 19.01% | 49,920,315 | | Hangzhou Panyuan Investment Co., Ltd. | 15.33% | 40,260,815 | | Xiamen Silicon Valley Shaohua I Investment Partnership | 10.01% | 26,273,850 | | Hangzhou Panhong Investment Management Partnership | 5.42% | 14,240,800 | - Of the shares held by controlling shareholder Hangzhou Panyuan Investment Co., Ltd., **22,282,825 shares are pledged**, representing **55.35%** of its holdings; its concerted party, Hangzhou Panhong Investment Management Partnership (Limited Partnership), has **9,500,000 shares pledged**[139](index=139&type=chunk)[669](index=669&type=chunk) [Bond-Related Information](index=41&type=section&id=第七节%20债券相关情况) [Bond Status](index=41&type=section&id=债券情况) The company had no bond-related information during the reporting period [Financial Report](index=42&type=section&id=第八节%20财务报告) [Financial Statements](index=42&type=section&id=财务报表) This unaudited semi-annual financial report presents the consolidated balance sheet, income statement, and cash flow statement, detailing the company's assets, liabilities, equity, revenue, costs, and cash flows for the period Consolidated Balance Sheet Summary (June 30, 2025) | Item | Period-End Balance (billion yuan) | Beginning-of-Period Balance (billion yuan) | | :--- | :--- | :--- | | Total Assets | 1.44 | 1.46 | | Total Liabilities | 0.33 | 0.34 | | Total Equity Attributable to Parent Company Owners | 1.10 | 1.11 | Consolidated Income Statement Summary (H1 2025) | Item | Current Period Amount (million yuan) | Prior Period Amount (million yuan) | | :--- | :--- | :--- | | Total Operating Revenue | 158.88 | 160.46 | | Total Operating Costs | 150.64 | 168.68 | | Net Profit | -3.68 | -14.56 | | Net Profit Attributable to Parent Company Shareholders | -3.52 | -14.33 | Consolidated Cash Flow Statement Summary (H1 2025) | Item | Current Period Amount (million yuan) | Prior Period Amount (million yuan) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | -64.99 | -96.29 | | Net Cash Flow from Investing Activities | -40.74 | 9.98 | | Net Cash Flow from Financing Activities | -33.56 | -0.95 | | Net Increase in Cash and Cash Equivalents | -139.30 | -87.26 | [Notes to Financial Statements](index=60&type=section&id=财务报表附注) The notes detail the company's background, financial statement preparation basis, and significant accounting policies, including revenue recognition, R&D capitalization, and financial instrument impairment, with no major policy changes and tax benefits as a key software enterprise - The company's revenue recognition policy for **digital scenario application system implementation business** is based on the input method according to the progress of performance; for **medical information system software sales and development**, revenue is recognized when the customer confirms and the right to receive payment is obtained[313](index=313&type=chunk)[315](index=315&type=chunk) - R&D expenditure capitalization policy: The company begins capitalization after completing the project design, meeting expected requirements, and passing project approval, ceasing capitalization and transferring to intangible assets upon completion of development into standardized products ready for delivery[296](index=296&type=chunk) - The company enjoys tax incentives, including **immediate refund of VAT exceeding 3% for software products** and a **temporary 10% corporate income tax rate for 2025** as a key software enterprise within national planning[360](index=360&type=chunk)

康希诺生物股份公司2025 年半年度报告 公司代码：688185 公司简称：康希诺 康希诺生物股份公司 2025 年半年度报告 1 / 184 康希诺生物股份公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已在本报告"第三节 管理层讨论与分析"之"四、风险因素"中说明了可能对公司产生 重大不利影响的风险因素，敬请投资者注意投资风险。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人XUEFENG YU（宇学峰）、主管会计工作负责人刘明及会计机构负责人（会计 主管人员）高蓓蓓声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性陈述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 九 ...

安徽宏宇五洲医疗器械股份有限公司 2025 年半年度报告 二〇二五年八月二十日 安徽宏宇五洲医疗器械股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人黄凡、主管会计工作负责人季宇及会计机构负责人(会计主管 人员)季宇声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中如有涉及未来的计划、业绩预测等方面的内容，均不构成公司对 任何投资者及相关人士的实质承诺，投资者及相关人士均应对此保持足够的 风险认识，并且应当理解计划、预测与承诺之间的差异。敬请投资者注意投 资风险。 本公司敬请投资者认真阅读本报告全文，并特别注意公司在经营中可能面 临的行业周期性波动风险、市场竞争日益加剧风险、产品质量控制风险、持 续研发与创新风险、毛利率下滑风险、汇率波动风险、应收账款回款风险及 客户流失等风险因素，注意投资风险。具体内容详见本报告第三节"管理层 讨论与分析"之"十、公司面临的风险和 ...

重药控股股份有限公司 2025 年半年度报告 2025 年 8 月 重药控股股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法 律责任。 公司负责人袁泉、主管会计工作负责人杨磊及会计机构负责人(会计主管 人员)殷怡声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 公司可能存在行业竞争、经营与管理、市场、国家政策等风险，敬请广 大投资者注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | | | | 第一节 | 重要提示、目录和释义 | 2 | | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 | 6 | | 第三节 | 管理层讨论与分析 | 9 | | 第九节 | 其他报送数据 201 | | 重药控股股份有限公司 2025 年半年度报告全文 备查文件目录 （一）公司负责人、主管会计工作负责人、会计机构负责人签名并盖章的财务报表。 （二）报告期内在中国证 ...

浙江聚力文化发展股份有限公司 2025 年半年度报告 2025 年 8 月 浙江聚力文化发展股份有限公司 2025 年半年度报告全文 1 浙江聚力文化发展股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法 律责任。 公司负责人王炳毅、主管会计工作负责人杜锡琦及会计机构负责人(会计 主管人员)杜锡琦声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中涉及的公司关于未来发展战略、经营计划等前瞻性陈述不构成 公司对投资者的实质承诺，投资者及相关人士均应当对此保持足够的风险认 识，并且应当理解计划、预测与承诺之间的差异。 公司在本报告第三节《管理层讨论与分析》的"公司面临的风险和应对措 施"中对公司可能面对的风险进行了陈述，敬请投资者认真阅读并注意投资风 险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 4 | | --- | | 4 | | 第一节 | 重要提示、目录和释义 | 2 | | ...